Switch theme
Sign up to access all valuation multiples
Fleury SA is engaged in the provision of medical services in the diagnostic, treatment, clinical analysis, health management, medical care, orthopedics and ophthalmology areas and offers its digital healthcare platform. The company carries out its activities through customer service units and hospital-based units. Furthermore, the company has a mobile service operation with coverage in municipalities in addition to a digital platform. It has two reportable business segments: Diagnostic Medicine and Integrated Medicine. The maximum revenue is generated from Diagnostic Medicine Segment.
1926
22.9K+
LTM Revenue $1.4B
LTM EBITDA $360M
$1.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Fleury has a last 12-month revenue (LTM) of $1.4B and a last 12-month EBITDA of $360M.
In the most recent fiscal year, Fleury achieved revenue of $1.4B and an EBITDA of $369M.
Fleury expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Fleury valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| Gross Profit | $389M | XXX | $377M | XXX | XXX | XXX |
| Gross Margin | 28% | XXX | 28% | XXX | XXX | XXX |
| EBITDA | $360M | XXX | $369M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 27% | XXX | XXX | XXX |
| EBIT | $219M | XXX | $217M | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $114M | XXX | $108M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 8% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $717M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Fleury's stock price is BRL 13 (or $2).
Fleury has current market cap of BRL 7.0B (or $1.2B), and EV of BRL 10.0B (or $1.8B).
See Fleury trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.8B | $1.2B | XXX | XXX | XXX | XXX | $0.21 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Fleury has market cap of $1.2B and EV of $1.8B.
Fleury's trades at 1.3x EV/Revenue multiple, and 4.8x EV/EBITDA.
Equity research analysts estimate Fleury's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Fleury has a P/E ratio of 10.8x.
See valuation multiples for Fleury and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV (current) | $1.8B | XXX | $1.8B | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | 4.9x | XXX | 4.8x | XXX | XXX | XXX |
| EV/EBIT | 8.0x | XXX | 8.1x | XXX | XXX | XXX |
| EV/Gross Profit | 4.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 10.8x | XXX | 11.4x | XXX | XXX | XXX |
| EV/FCF | 12.3x | XXX | 7.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialFleury's last 12 month revenue growth is 7%
Fleury's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $7K for the same period.
Fleury's rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Fleury's rule of X is 43% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Fleury and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | 12% | XXX | XXX | XXX |
| Rule of 40 | 33% | XXX | 34% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 43% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $7K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Fleury acquired XXX companies to date.
Last acquisition by Fleury was XXXXXXXX, XXXXX XXXXX XXXXXX . Fleury acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Fleury founded? | Fleury was founded in 1926. |
| Where is Fleury headquartered? | Fleury is headquartered in Brazil. |
| How many employees does Fleury have? | As of today, Fleury has 22.9K+ employees. |
| Is Fleury publicy listed? | Yes, Fleury is a public company listed on BVMF. |
| What is the stock symbol of Fleury? | Fleury trades under FLRY3 ticker. |
| When did Fleury go public? | Fleury went public in 2009. |
| Who are competitors of Fleury? | Similar companies to Fleury include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Fleury? | Fleury's current market cap is $1.2B |
| What is the current revenue of Fleury? | Fleury's last 12 months revenue is $1.4B. |
| What is the current revenue growth of Fleury? | Fleury revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Fleury? | Current revenue multiple of Fleury is 1.3x. |
| Is Fleury profitable? | Yes, Fleury is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Fleury? | Fleury's last 12 months EBITDA is $360M. |
| What is Fleury's EBITDA margin? | Fleury's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Fleury? | Current EBITDA multiple of Fleury is 4.9x. |
| What is the current FCF of Fleury? | Fleury's last 12 months FCF is $144M. |
| What is Fleury's FCF margin? | Fleury's last 12 months FCF margin is 10%. |
| What is the current EV/FCF multiple of Fleury? | Current FCF multiple of Fleury is 12.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
